Citation Impact
Citing Papers
Membrane-tethered mucin-like polypeptides sterically inhibit binding and slow fusion kinetics of influenza A virus
2020 StandoutNobel
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
2014
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
A sex-biased imbalance between Tfr, Tph, and atypical B cells determines antibody responses in COVID-19 patients
2023 StandoutNobel
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells
2016
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Intraperitoneal prophylaxis with CpG oligodeoxynucleotides protects neutropenic mice against intracerebral Escherichia coli K1 infection
2014
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
CD22 blockade restores homeostatic microglial phagocytosis in ageing brains
2019 StandoutNatureNobel
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?
2017
Current Clinical Trials Testing Combinations of Immunotherapy and Radiation
2014
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Evolving synergistic combinations of targeted immunotherapies to combat cancer
2015
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
2015
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
2015
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
2016
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
2017
EMT: 2016
2016 Standout
Hypoxia: Signaling the Metastatic Cascade
2016
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
2017
PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment
2022 StandoutNobel
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity
2015
Molecular therapies and precision medicine for hepatocellular carcinoma
2018
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
2017
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Cervical cancer
2019 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Small RNAs are modified with N-glycans and displayed on the surface of living cells
2021 StandoutNobel
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
2019 StandoutNobel
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Hepatocellular Carcinoma
2019 Standout
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models
2021
Regulatory T Cells and Human Disease
2020 StandoutNobel
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Nanoscale covalent organic frameworks as theranostic platforms for oncotherapy: synthesis, functionalization, and applications
2020
Targeting Treg cells in cancer immunotherapy
2019 StandoutNobel
Dynamic Transformation between Covalent Organic Frameworks and Discrete Organic Cages
2020 StandoutNobel
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Spermidine in health and disease
2018 StandoutScience
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
DNA origami protection and molecular interfacing through engineered sequence-defined peptoids
2020 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity
2014
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Proenkephalin+regulatory T cells expanded by ultraviolet B exposure maintain skin homeostasis with a healing function
2020 StandoutNobel
Translating Immunology into Therapeutic Concepts for Inflammatory Bowel Disease
2018
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
2017 StandoutNobel
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
2018
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
2014 StandoutNobel
Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells
2021 StandoutNobel
Local checkpoint inhibition of CTLA‐4 as a monotherapy or in combination with anti‐PD1 prevents the growth of murine bladder cancer
2016
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
2017
Genetics and biology of pancreatic ductal adenocarcinoma
2016
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
2014
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Oncolytic Viruses in Cancer Treatment
2016
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Works of Aurélien Marabelle being referenced
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
2013
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
2016
Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors
2015
Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
2016
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
2015
Radiotherapy and Toll-Like Receptor Agonists
2014
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
2016
Paradigm shift in oncology: targeting the immune system rather than cancer cells
2015
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
2015
Tumour burden and efficacy of immune-checkpoint inhibitors
2021
Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy
2011
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
2013
Pattern recognition receptors: immune targets to enhance cancer immunotherapy
2017
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
2017
Rationale for anti-OX40 cancer immunotherapy
2015
Hyperprogressive disease: recognizing a novel pattern to improve patient management
2018
Gastrointestinal Immune Related Adverse Events Associated with Programmed-Death 1 Blockade
2017
P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade
2017
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
2013
Intratumoral Immunization: A New Paradigm for Cancer Therapy
2014
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
2016
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers
2020
Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
2018
Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.
2018
T-cell–based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition
2015